Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate.
Assay of plasma methotrexate has been established as important to its safe use. We have investigated the specificity of 2 assay procedures for methotrexate: the competitive dihydrofolate reductase binding assay (CRBA) and the radioimmunoassay (RIA). The RIA of plasma methotrexate resulted in consistently higher values than the CRBA, with greater differences at later measurement times. A compound that strongly cross-reacts in the RIA, but not the CRBA, has been identified in plasma and urine of patients on high-dose methotrexate therapy, and appears to be the carboxypeptidase cleavage product (2,4-diamino-N10-methylpteroic acid) on the basis of chromatographic and ultraviolet spectral properties. Although this compound is present as a minor contaminant in commercial methotrexate preparations, quantitative assessment of urinary excretion suggests that in man a major portion of the compound is derived from methotrexate metabolism.
D001681:Biological Assay; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D004340:Drug Contamination; D005493:Folic Acid Antagonists; D006801:Humans; D008722:Methods; D008727:Methotrexate / Q000031:analogs & derivatives* / Q000032:analysis / Q000378:metabolism*; D011863:Radioimmunoassay; D012995:Solubility; D013056:Spectrophotometry, Ultraviolet
D005493:Folic Acid Antagonists; D008727:Methotrexate